Novavax (NVAX) volatility elevated into Phase III RSV vaccine data

August 8, 2016 1:44 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Novavax (NASDAQ: NVAX) August call option implied volatility is at 102, September is at 159; compared to its 52-week range of 61 to 140 into the expected release of Q2 results on August 9 and Phase III RSV vaccine data in Q3.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Options, Trader Talk

Related Entities

Options

Add Your Comment